Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Serine/threonine protein kinase which phosphorylates VIME. Additionally we are shipping STK33 Proteins (8) and and many more products for this protein.
Showing 10 out of 125 products:
Human Monoclonal STK33 Primary Antibody for IP, ELISA - ABIN566312
Scholl, Fröhling, Dunn, Schinzel, Barbie, Kim, Silver, Tamayo, Wadlow, Ramaswamy, Döhner, Bullinger, Sandy, Boehm, Root, Jacks, Hahn, Gilliland: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. in Cell 2009
Show all 2 Pubmed References
Human Monoclonal STK33 Primary Antibody for IF, IP - ABIN566314
Babij, Zhang, Kurzeja, Munzli, Shehabeldin, Fernando, Quon, Kassner, Ruefli-Brasse, Watson, Fajardo, Jackson, Zondlo, Sun, Ellison, Plewa, San, Robinson, McCarter, Schwandner, Judd, Carnahan, Dussault: STK33 kinase activity is nonessential in KRAS-dependent cancer cells. in Cancer research 2011
Show all 2 Pubmed References
Dysregulated HIF1alpha (show HIF1A Antibodies)/STK33 signaling promotes pancreatic ductal adenocarcinoma (PDAC) growth and progression, this suggests that STK33 is a candidate therapeutic target to improve PDAC treatment.
STK33 is a potential oncogene (show RAB1A Antibodies) and plays an important role in tumorigenesis of HSCC via regulation of numerous genes.
STK33 plays an essential role in hepatocellular proliferation and liver tumorigenesis. STK33 may bind directly to c-Myc (show MYC Antibodies) and increase its transcriptional activity.
Results show that STK33 is a potential oncogene (show RAB1A Antibodies) and a promising diagnostic marker for hypopharyngeal squamous cell carcinoma (HSCC). STK33 may promote tumorigenesis and progression of HSCC, and serve as a valuable molecular target for treatment of HSCC.
STK33 can promote cell migration and invasion and suppress p53 (show TP53 Antibodies) gene expression in the NL9980 and L9981 large cell lung cancer cell lines. In addition, this protein also promotes epithelial-mesenchymal transition.
The STK33-linked SNP rs4929949 is associated with obesity and BMI in two independent cohorts of Swedish and Greek children.
STK33 downregulation or dominant mutant overexpression had no effect on KRAS signaling or survival of cancer cells.
STK33/Stk33 expression pattern resembles those of some related members of the calcium/calmodulin dependent kinase (show CAMK2 Antibodies) group
Stk33 protein resides in the cytoplasm and partially co-localizes with the caudal (show CAD Antibodies) end of the manchette, a transient structure that guides tail elongation, in elongating spermatids, and loss of Stk33 leads to the appearance of a tight, straight and elongated manchette.
Double-immunostaining experiments with antibodies against Stk33 and vimentin (show VIM Antibodies) showed a striking colocalization of Stk33 and vimentin (show VIM Antibodies) in the hypothalamus.
STK33 promotes cancer cell viability in a kinase activity-dependent manner by regulating the suppression of mitochondrial apoptosis mediated through S6K1-induced inactivation of the death agonist BAD selectively in mutant KRAS-dependent cells.
Serine/threonine protein kinase which phosphorylates VIME. May play a specific role in the dynamic behavior of the intermediate filament cytoskeleton by phosphorylation of VIME (By similarity).
serine/threonine-protein kinase 33